Update on the Pathogenesis, Virulence, and Treatment of Candida auris.

Q1 Medicine Pathogens and Immunity Pub Date : 2022-01-01 DOI:10.20411/pai.v7i2.535
Richard R Watkins, Rachael Gowen, Michail S Lionakis, Mahmoud Ghannoum
{"title":"Update on the Pathogenesis, Virulence, and Treatment of <i>Candida auris</i>.","authors":"Richard R Watkins,&nbsp;Rachael Gowen,&nbsp;Michail S Lionakis,&nbsp;Mahmoud Ghannoum","doi":"10.20411/pai.v7i2.535","DOIUrl":null,"url":null,"abstract":"<p><p><i>Candida auris</i> is an emerging, multidrug resistant fungal pathogen that causes considerable morbidity and mortality. First identified in Japan in 2009, it has since been reported in more than 40 countries. <i>C. auris</i> can persist for long periods on different environmental surfaces as well as the skin. Clinical isolates are typically resistant to commonly prescribed antifungal drugs. Increasingly recognized as a cause of infections and outbreaks in nosocomial settings, <i>C. auris</i> is difficult to identify using traditional microbiological methods. One of the main reasons for the ongoing spread of <i>C. auris</i> is the multitude of virulence factors it possesses and uses against its human host that enables fungal persistence on the skin surface. Yet, many of the virulence mechanismsare unknown or remain incompletely understood. In this review, we summarize the evolution of virulence of <i>C. auris</i>, offer recommendations for combating this important human pathogen, and suggest directions for further research.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":"7 2","pages":"46-65"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620957/pdf/","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and Immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20411/pai.v7i2.535","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 15

Abstract

Candida auris is an emerging, multidrug resistant fungal pathogen that causes considerable morbidity and mortality. First identified in Japan in 2009, it has since been reported in more than 40 countries. C. auris can persist for long periods on different environmental surfaces as well as the skin. Clinical isolates are typically resistant to commonly prescribed antifungal drugs. Increasingly recognized as a cause of infections and outbreaks in nosocomial settings, C. auris is difficult to identify using traditional microbiological methods. One of the main reasons for the ongoing spread of C. auris is the multitude of virulence factors it possesses and uses against its human host that enables fungal persistence on the skin surface. Yet, many of the virulence mechanismsare unknown or remain incompletely understood. In this review, we summarize the evolution of virulence of C. auris, offer recommendations for combating this important human pathogen, and suggest directions for further research.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
耳念珠菌的发病机制、毒力和治疗进展。
耳念珠菌是一种新兴的多药耐药真菌病原体,引起相当大的发病率和死亡率。2009年首次在日本被发现,此后在40多个国家都有报道。耳念珠菌可以在不同的环境表面和皮肤上存活很长时间。临床分离株通常对常用的抗真菌药物具有耐药性。人们越来越多地认识到,金黄色葡萄球菌是医院环境中感染和暴发的原因,但很难用传统的微生物学方法识别。金黄色葡萄球菌持续传播的主要原因之一是它拥有并用于对抗人类宿主的多种毒力因子,使真菌能够在皮肤表面持续存在。然而,许多毒力机制尚不清楚或仍未完全了解。本文综述了金黄色葡萄球菌毒力的演变,并对今后防治这一重要的人类病原体提出了建议,同时提出了今后的研究方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pathogens and Immunity
Pathogens and Immunity Medicine-Infectious Diseases
CiteScore
10.60
自引率
0.00%
发文量
16
审稿时长
10 weeks
期刊最新文献
Inflammation and Microbial Translocation Correlate with Reduced MAIT Cells in People with HIV. Historical Highlight: The Luria-Delbrück Fluctuation Test - A Study of the Nature of Bacterial Mutations Conferring Resistance to Infection by Bacteriophage. Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies. Jonathan Yewdell Discusses Viral Immunology, Vaccine Development, Navigating a Scientific Career, and Offers Perspectives on Transforming Scientific Publishing and Research Education. Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1